← Back to Search

Tyrosine Kinase Inhibitor

Cabozantinib + Pemetrexed for Non-Small Cell Lung Cancer

Phase 1
Waitlist Available
Led By Nagla A Karim, MD, PhD
Research Sponsored by Augusta University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years or older.
Locally advanced NSCLC, urothelial cancer or malignant mesothelioma.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up os measured through study completion, and an average of 1 year
Awards & highlights

Study Summary

This trial will explore whether combining cabozantinib with pemetrexed can effectively treat patients with advanced non-small cell lung cancer, urothelial cancer, or malignant mesothelioma.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Bladder Cancer
  • Mesothelioma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~to be measured through study completion; an average of 1 year.
This trial's timeline: 3 weeks for screening, Varies for treatment, and to be measured through study completion; an average of 1 year. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assess the maximum tolerated dose (MTD) of cabozantinib in combination with pemetrexed
Secondary outcome measures
Heart rate
Overall survival (OS).
Progression-free survival (PFS)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Cabozantinib + PemetrexedExperimental Treatment2 Interventions
Pemetrexed 500mg/m2 IV day 1 of each 21 day cycle + Cabozantinib 20-60mg by mouth once a day.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cabozantinib
2020
Completed Phase 2
~1080
Pemetrexed
2014
Completed Phase 3
~5250

Find a Location

Who is running the clinical trial?

Augusta UniversityLead Sponsor
210 Previous Clinical Trials
85,047 Total Patients Enrolled
Nagla A Karim, MD, PhDPrincipal InvestigatorAugusta University Georgia Cancer Center
1 Previous Clinical Trials
10 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~2 spots leftby Mar 2025